EGFR and non-small cell lung carcinoma: However, there is no conclusive evidence whether neoadjuvant targeted therapy has clinical application value for EGFR-mutated resectable NSCLC and whether neoadjuvant targeted therapy is superior to neoadjuvant chemotherapy.